| 10.91 -0.73 (-6.27%) | 07-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.08  |
1-year : | 16.45 |
| Resists | First : | 12.06 |
Second : | 14.08 |
| Pivot price | 9.51 |
|||
| Supports | First : | 9.12 |
Second : | 7.31 |
| MAs | MA(5) : | 10.88 |
MA(20) : | 9.05 |
| MA(100) : | 10.15 |
MA(250) : | 10.62 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 87.7 |
D(3) : | 93.1 |
| RSI | RSI(14): 66.4 |
|||
| 52-week | High : | 14.93 | Low : | 7.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ORIC ] has closed below upper band by 17.6%. Bollinger Bands are 35.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.07 - 12.13 | 12.13 - 12.17 |
| Low: | 10.76 - 10.84 | 10.84 - 10.88 |
| Close: | 10.8 - 10.92 | 10.92 - 10.99 |
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Mon, 06 Jul 2026
ORIC (NASDAQ) Form 144: Affiliate notifies sale of 7,000 Common shares via J.P. Morgan - Stock Titan
Mon, 06 Jul 2026
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
Sat, 04 Jul 2026
Price to earnings forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Thu, 02 Jul 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Thu, 11 Jun 2026
Stifel initiates Oric Pharmaceuticals stock with buy rating - Investing.com
Wed, 10 Jun 2026
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 114.1 (%) |
| Shares Short | 21,060 (K) |
| Shares Short P.Month | 21,940 (K) |
| EPS | -1.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.6 % |
| Return on Equity (ttm) | -42.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -68 (M) |
| PE Ratio | -7.85 |
| PEG Ratio | 0 |
| Price to Book value | 2.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|